

Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine

Marion Plaze^{1,2†}, David Attali^{1,2,3†}, Matthieu Prot^{4†}, Anne-Cécile Petit^{1,5}, Michael Blatzer⁵, Fabien Vinckier^{1,2}, Laurine Levillayer⁶, Florent Perin-Dureau⁷, Arnaud Cachia^{8,9}, Gérard Friedlander², Fabrice Chrétien^{2,5,10‡}, Etienne Simon-Loriere^{4‡}, Raphaël Gaillard^{1,2,5‡}

1. GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France
2. Université de Paris, Paris, France
3. Physics for Medicine Paris, Inserm, ESPCI Paris, CNRS, PSL Research University, Univ Paris Diderot, Sorbonne Paris Cite, Paris, France
4. Institut Pasteur, G5 Evolutionary Genomics of RNA Viruses, Paris, France
5. Institut Pasteur, Experimental Neuropathology Unit, Paris, France
6. Institut Pasteur, Unité de Génétique Fonctionnelle des Maladies Infectieuses, Paris, France
7. Department of Anesthesiology, Fondation Rothschild; ASMR-II Consulting; Regstem; Paris, France
8. Université de Paris, Laboratoire de Psychologie du développement et de l'Education de l'Enfant, CNRS, Paris, France
9. Université de Paris, Institut de Psychiatrie et Neurosciences de Paris, INSERM, Paris, France
10. GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service de Neuropathologie, Paris, France

† These authors share first author position.

‡ These authors co supervised this work.

Correspondence: r.gaillard@ghu-paris.fr, etienne.simon-loriere@pasteur.fr or m.plaze@ghu-paris.fr

Abstract

Urgent action is needed to fight the ongoing COVID-19 pandemic by reducing the number of infected people along with the infection contagiousness and severity. Chlorpromazine (CPZ), the prototype of typical antipsychotics from the phenothiazine group, is known to inhibit clathrin-mediated endocytosis and acts as an antiviral, in particular against SARS-CoV-1 and MERS-CoV. In this study, we describe the *in vitro* testing of CPZ against a SARS-CoV-2 isolate in monkey and human cells. We evidenced an antiviral activity against SARS-CoV-2 with an IC50 of ~10µM. Because of its high biodistribution in lung, saliva and brain, such IC50 measured *in vitro* may translate to CPZ dosage used in clinical routine. This extrapolation is in line with our observations of a higher prevalence of symptomatic and severe forms of COVID-19 infections among health care professionals compared to patients in psychiatric wards. These preclinical findings support the repurposing of CPZ, a largely used drug with mild side effects, in COVID-19 treatment.

To the Editor: From the beginning of the COVID-19 outbreak several weeks ago, we observed in Sainte Anne hospital (GHU PARIS Psychiatrie & Neurosciences, Paris, France) a higher prevalence of symptomatic and severe forms of COVID-19 infections among health care professionals (~14%) compared to patients in psychiatric wards (~4%) (1). This unexpected finding, that patients with higher comorbidities and risk factors (overweight, cardiovascular disorders...) seem to be protected against symptomatic and severe forms of COVID-19, drew our interest to decipher putative factors that could mediate this anti-SARS-CoV-2 protection. Because patients in psychiatric wards benefit from psychotropic medications, we screened the literature for

antiviral effects associated with those drugs. This literature analysis identified chlorpromazine (CPZ), the prototype of phenothiazine-type antipsychotics, as the lead candidate (1). Indeed, CPZ has been widely used in clinical routine in the treatment of acute and chronic psychoses for decades. This first antipsychotic medication was discovered in 1952 by Jean Delay and Pierre Deniker at Sainte Anne hospital (2). In addition to its antipsychotic activity, a growing body of *in vitro* studies has demonstrated antiviral properties, for example against influenza (3), hepatitis viruses (4), alphaviruses (5), JC virus (6), Japanese encephalitis virus (7), bronchitis-virus (8), MHV-2 (9), Zika virus (10) or dengue virus (11). CPZ has also been shown to have antiviral activity against coronaviruses in multiple studies (12–14). It was identified active against both MERS-CoV and SARS-CoV-1 in a screen of 348 FDA-approved drugs, together with three other compounds (chloroquine, loperamide, lopinavir), using different cell lines (12). Similar results were obtained in a different library screen (13), as well as in another study using primary human monocytes (14). The genetic similarity between SARS-CoV-1 and SARS-CoV-2 suggests that this effect could also apply to this novel coronavirus. The antiviral activity of CPZ is mainly associated to inhibition of clathrin-mediated endocytosis (15–18), via translocation of clathrin and AP2 from the cell surface to intracellular endosomes (16). This clathrin-mediated endocytosis is essential for coronavirus cell entry (19). A very recent review article underlines the therapeutic potential of targeting clathrin-mediated endocytosis to tackle SARS-CoV-2 (20).

In this context, the aim of the current study was to investigate CPZ antiviral activity against SARS-CoV-2 in an *in vitro* assay. We therefore infected monkey VeroE6 cells with SARS-CoV-2 at a MOI of 0.1 for 2 h, in presence of different concentrations of CPZ. Supernatants were harvested at day 2 and analyzed by RT-qPCR for the presence of SARS-CoV-2 RNA (Figure 1.A). In parallel, cell viability was assessed on non-infected cells. While CPZ was associated with a cytotoxic effect in this model at the highest doses assessed, we measured an antiviral activity against SARS-CoV-2, with an IC₅₀ of 9 μ M. We also measured the viral RNA production in human A549-ACE2 cells (MOI of 1), where the cytotoxicity of CPZ was less pronounced (Figure 1.B), estimating an IC₅₀ of 10.4 μ M. These findings warrant further clinical investigations. Indeed, the biodistribution of CPZ (Figure 2) is highly compatible with the tropism of SARS-CoV-2: preclinical and clinical studies have reported high CPZ concentration in the lungs (20-200 times higher than in plasma (21–24)) and in saliva (30-100 times higher than in plasma (22,25)). Finally, CPZ readily crosses the blood-brain barrier (21–23,26) and could therefore prevent the neurological forms of COVID-19 (27).

With 2 900 000 infections and more than 200 000 deaths worldwide in just a few months (28), tools are urgently needed to help against the SARS-CoV-2 pandemic, to diminish disease severity along with contagiousness and to reduce the socio-economic consequences of the pandemic. Repurposing CPZ, a molecule already used in clinical practice, could offer both ready-to-use treatment with well-known and very mild side effects but also prophylactic strategy for the time after the lock down. At this time, CPZ is prescribed for around 70 years and FDA-approved in psychiatry and anesthesiology, with an excellent tolerance profile. CPZ is also used in clinical routine in nausea and vomiting of pregnancy (29), in advanced cancer (30), and to treat headaches in various neurological conditions (31). Even though the extrapolation from *in vitro* to clinically relevant dosage is not straightforward, the IC₅₀ of 10 μ M (*i.e.* 3189 ng/ml; CPZ molar mass = 318.86 g/mol) measured *in vitro* may be compatible with CPZ dosage used in clinical routine. Indeed, residual plasma levels of CPZ in patients range from 30 to 300 ng/ml (32), which corresponds to 600 – 60 000 ng/ml in lungs (21–24) and 900 – 30 000 ng/ml in saliva (22,25). This extrapolation is supported by our observation of lower prevalence of symptomatic and severe forms of COVID-19 infections in psychiatric patients.

In conclusion, this first *in vitro* study of CPZ antiviral activity against SARS-CoV-2 in monkey and human cells supports the repurposing of CPZ, a well-known drug with antiviral properties and an excellent tolerance profile, to treat the actual COVID-19 pandemic for which effective treatments are still lacking. This proof of principle for the feasibility of CPZ as anti-SARS-CoV-2 therapeutic is a critical step for ongoing clinical trial (NCT04366739).




Figure 1. Antiviral activity of CPZ against SARS-CoV-2 in vitro in monkey VeroE6 cells (A) and human A549-ACE2 cells (B). Viral load in supernatants were measured at 48h (left Y axis), and viability under increasing concentrations of the antiviral compound are shown. Error bars denote s.e.m.




Figure 2. Review of temporal CPZ biodistribution in lung, saliva and brain. Ratio of tissue to plasma CPZ concentrations (log scale) after administration of a single dose of CPZ are represented for lung (red), saliva or salivary glands (yellow) and brain (blue) in rodents (filled) and humans (no-filled). Derived from previous preclinical and clinical studies (21–23,25,26,33).

Material & Methods

Cell culture and virus isolates

Vero E6 cells (African green monkey kidney epithelial cells, ATCC, CRL-1586) were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and 5 units/mL penicillin and 5 $\mu\text{g}/\text{mL}$ streptomycin at 37°C with 5% CO₂. A549-ACE2 cells (adenocarcinomic human alveolar basal epithelial

cells, transduced to express the human Angiotensin-converting enzyme 2 (ACE2), kind gift of Pr. O. Schwartz, Institut Pasteur, Paris France) were maintained in DMEM containing 10% FBS, 5 units/mL penicillin and 5 µg/mL streptomycin and 40 µg/mL blasticidin at 37°C with 5% CO₂.

SARS-CoV-2, isolate BetaCoV/France/IDF0372/2020 C2, was supplied by the National Reference Centre for Respiratory Viruses (NRC) hosted at Institut Pasteur (Paris, France) and headed by Pr. S. Van der Werf. The human sample from which this strain was isolated has been provided by Dr. X. Lescure and Pr. Y. Yazdanpanah from the Bichat Hospital, Paris, France. Viral stocks were prepared by propagation in VeroE6 cells in DMEM supplemented with 2% FBS. Viral titers were determined by plaque assay. All experiments involving live SARS-CoV-2 were performed in compliance with Institut Pasteur guidelines for Biosafety Level 3 work. All experiments were performed in at least three biologically independent replicates.

Antiviral activity assay

Cells were seeded into 96-well plates 24 h prior to the experiment. Two hours prior to infection, cell culture supernatant was replaced with media containing 32µM, 16µM, 8µM, 4µM and 2µM of CPZ, or the equivalent volume of maximum H₂O vehicle used as a control. For the infection, the drug-containing media was removed, and replaced with virus inoculum (MOI of 0.1 PFU/cell for VeroE6 and 1 for A549-ACE2) for 2 hours. The inoculum was then removed and replaced with 100µl fresh media (2% FBS) containing CPZ at the indicated concentrations or H₂O and incubated for 48 hours.

At 48h, cell supernatant was collected and spun for 5 min at 3,000g to remove debris. Toxicity controls were setup in parallel on uninfected cells.

RNA was extracted from 50µl aliquots of supernatant using the Nucleospin 96 virus kit (Macherey-Nagel) following the manufacturer's instructions. Detection of viral genomes was performed by RT-qPCR, using the IP4 primer set developed by the NRC at Institut Pasteur (described on the WHO website (https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2)). RT-qPCR was performed using the Luna Universal One-Step RT-qPCR Kit (NEB) in an Applied Biosystems QuantStudio 3 thermocycler, using the following cycling conditions: 55°C for 10 min, 95°C for 1 min, and 40 cycles of 95°C for 10 sec, followed by 60°C for 1 min. The quantity of viral genomes is expressed as PFU equivalents, and was calculated by performing a standard curve with RNA derived from a viral stock with a known viral titer. IC₅₀ values were fitted using four-parameter dose response curves in GraphPad prism v8.4.2.

Cell viability in drug-treated cells was measured using the AlamarBlue reagent (ThermoFisher). At 48 h post treatment, the drug-containing media was removed and replaced with AlamarBlue and incubated for 2h at 37°C. Fluorescence was measured in a Tecan Infinity 2000 plate reader. Percentage viability was calculated relative to untreated cells (100% viability).

Acknowledgments

We are grateful to the Centre National de Reference des virus des infections respiratoires for sharing reagents and protocols. We thank Olivier Schwartz and his team for sharing the A549-ACE2 cell line. This study has received funding from Institut Pasteur (covid-therap) and the French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (grant n°ANR-10-LABX-62-IBED). ESL acknowledges funding from the INCEPTION program (Investissements d'Avenir grant ANR-16-CONV-0005).

Competing interest

The authors have no competing interest.

References


1. Plaze M, Attali D, Petit A-C, Blatzer M, Simon-Loriere E, Vinckier F, et al. Repositionnement de la chlorpromazine dans le traitement du COVID-19: étude reCoVery. *L'Encéphale*. 2020 Apr 15;
2. Delay J, Deniker P, Harl JM. [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)]. *Ann Med Psychol (Paris)*. 1952 Jun;110(2 1):112–7.

3. Krizanová O, Ciampor F, Veber P. Influence of chlorpromazine on the replication of influenza virus in chick embryo cells. *Acta Virol.* 1982 Jul;26(4):209–16.
4. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. *J Virol.* 2006 Jul;80(14):6964–72.
5. Pohjala L, Utt A, Varjak M, Lulla A, Merits A, Ahola T, et al. Inhibitors of Alphavirus Entry and Replication Identified with a Stable Chikungunya Replicon Cell Line and Virus-Based Assays. *PLOS ONE.* 2011 Dec 19;6(12):e28923.
6. Pho MT, Ashok A, Atwood WJ. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. *J Virol.* 2000 Mar;74(5):2288–92.
7. Nawa M, Takasaki T, Yamada K-I, Kurane I, Akatsuka T. Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorpromazine. *J Gen Virol.* 2003 Jul;84(Pt 7):1737–41.
8. Chu VC, McElroy LJ, Ferguson AD, Bauman BE, Whittaker GR. Avian infectious bronchitis virus enters cells via the endocytic pathway. *Adv Exp Med Biol.* 2006;581:309–12.
9. Pu Y, Zhang X. Mouse Hepatitis Virus Type 2 Enters Cells through a Clathrin-Mediated Endocytic Pathway Independent of Eps15. *Journal of Virology.* 2008 Aug 15;82(16):8112–23.
10. Persaud M, Martinez-Lopez A, Buffone C, Porcelli SA, Diaz-Griffero F. Infection by Zika viruses requires the transmembrane protein AXL, endocytosis and low pH. *Virology.* 2018;518:301–12.
11. Carro AC, Piccini LE, Damonte EB. Blockade of dengue virus entry into myeloid cells by endocytic inhibitors in the presence or absence of antibodies. *PLoS Negl Trop Dis.* 2018;12(8):e0006685.
12. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. *Antimicrob Agents Chemother.* 2014 Aug;58(8):4875–84.
13. Dyal J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. *Antimicrob Agents Chemother.* 2014 Aug;58(8):4885–93.
14. Cong Y, Hart BJ, Gross R, Zhou H, Frieman M, Bollinger L, et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. *PLOS ONE.* 2018 Mar 22;13(3):e0194868.
15. Daniel JA, Chau N, Abdel-Hamid MK, Hu L, von Kleist L, Whiting A, et al. Phenothiazine-derived antipsychotic drugs inhibit dynamin and clathrin-mediated endocytosis. *Traffic.* 2015 Jun;16(6):635–54.
16. Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. *J Cell Biol.* 1993 Dec;123(5):1107–17.
17. Chen F, Zhu L, Zhang Y, Kumar D, Cao G, Hu X, et al. Clathrin-mediated endocytosis is a candidate entry sorting mechanism for Bombyx mori cypovirus. *Sci Rep.* 2018 08;8(1):7268.
18. Inoue Y, Tanaka N, Tanaka Y, Inoue S, Morita K, Zhuang M, et al. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. *J Virol.* 2007 Aug;81(16):8722–9.
19. Burkard C, Verheije MH, Wicht O, Kasteren SI van, Kuppeveld FJ van, Haagmans BL, et al. Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner. *PLOS Pathogens.* 2014 Nov 6;10(11):e1004502.
20. Yang N, Shen H-M. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. *Int J Biol Sci.* 2020 Mar 15;16(10):1724–31.
21. Bickel MH, Graber BE, Moor M. Distribution of chlorpromazine and imipramine in adipose and other tissues of rats. *Life Sci.* 1983 Nov 14;33(20):2025–31.
22. Fujii T, Miyazaki H, Nambu K, Matsumoto K, Hashimoto M. Autoradiographic and biochemical studies of drug distribution in the liver. II. [35S]Chlorpromazine and [14C]imipramine. *Eur J Drug Metab Pharmacokinet.* 1984 Sep;9(3):247–55.
23. Sgaragli GP, Valoti M, Palmi M, Frosini M, Giovannini MG, Bianchi L, et al. Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. *J Pharm Pharmacol.* 1995 Sep;47(9):782–90.

24. Forrest IS, Bolt AG, Serra MT. Distribution of chlorpromazine metabolites in selected organs of psychiatric patients chronically dosed up to the time of death. *Biochem Pharmacol.* 1968 Oct;17(10):2061–70.
25. May PR, Van Putten T, Jenden DJ, Yale C, Dixon WJ. Chlorpromazine levels and the outcome of treatment in schizophrenic patients. *Arch Gen Psychiatry.* 1981 Feb;38(2):202–7.
26. Comar D, Zarifian E, Verhas M, Soussaline F, Maziere M, Berger G, et al. Brain distribution and kinetics of ¹¹C-chlorpromazine in schizophrenics: positron emission tomography studies. *Psychiatry Res.* 1979 Jul;1(1):23–9.
27. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun* [Internet]. 2020 Mar 30 [cited 2020 Apr 25]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146689/>
28. Situation update worldwide, as of 26 April 2020 [Internet]. European Centre for Disease Prevention and Control. [cited 2020 Apr 26]. Available from: <https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases>
29. Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy. *Obstet Gynecol.* 2018;131(1):e15–30.
30. Gupta M, Davis M, Walsh D, LeGrand S, Lagman R, Parala-Metz A. Nausea and Vomiting in Advanced Cancer—The Cleveland Clinic Protocol (TH310). *Journal of Pain and Symptom Management.* 2013 Feb 1;45(2):338–9.
31. Marmura MJ, Silberstein SD, Schwedt TJ. The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies. *Headache: The Journal of Head and Face Pain.* 2015;55(1):3–20.
32. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. *Pharmacopsychiatry.* 2018 Jan;51(1–02):9–62.
33. Wiesel FA, Alfredsson G. The distribution and metabolism of chlorpromazine in rats and the relationship to effects on cerebral monoamine metabolism. *Eur J Pharmacol.* 1976 Dec;40(2):263–72.


A.

Monkey VeroE6 cells




B.

Human A549-ACE2 cells



■ Antiviral activity ■ Cytotoxicity



Tissue

- Lung
- Saliva
- Brain

Species

- Rodents
- Humans

Study

- Bickel et al. 1983
- △ Comar et al. 1979
- Fujii et al. 1984
- May et al. 1981
- ◆ Sgaragli et al. 1995
- ▲ Wiesel et al. 1976